1. Home
  2. MDWD vs QUIK Comparison

MDWD vs QUIK Comparison

Compare MDWD & QUIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$16.40

Market Cap

212.1M

Sector

Health Care

ML Signal

HOLD

Logo QuickLogic Corporation

QUIK

QuickLogic Corporation

HOLD

Current Price

$19.07

Market Cap

211.8M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDWD
QUIK
Founded
2000
1988
Country
Israel
United States
Employees
N/A
51
Industry
Medicinal Chemicals and Botanical Products
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
212.1M
211.8M
IPO Year
2013
1997

Fundamental Metrics

Financial Performance
Metric
MDWD
QUIK
Price
$16.40
$19.07
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$36.00
$11.00
AVG Volume (30 Days)
53.9K
667.3K
Earning Date
05-20-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$20,112,000.00
Revenue This Year
$48.92
$75.17
Revenue Next Year
$35.04
$16.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.90
$4.80
52 Week High
$22.51
$22.69

Technical Indicators

Market Signals
Indicator
MDWD
QUIK
Relative Strength Index (RSI) 46.14 61.59
Support Level $16.31 $5.83
Resistance Level $18.38 N/A
Average True Range (ATR) 0.51 2.07
MACD -0.04 0.19
Stochastic Oscillator 30.10 63.21

Price Performance

Historical Comparison
MDWD
QUIK

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About QUIK QuickLogic Corporation

QuickLogic Corp is a fabless semiconductor company developing programmable logic semiconductor technologies, including embedded Field Programmable Gate Array (eFPGA) intellectual property (IP) and specialized FPGA devices. Its product offerings include the eFPGA IP licensing business and associated professional services, as well as a range of FPGA silicon products, including EOS, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II products, among others. The company's customers come from various markets, including aerospace and defense, industrial and infrastructure systems, data processing and computing platforms, and certain embedded and edge computing applications. Geographically, it generates maximum revenue from North America and the rest from Asia Pacific and Europe.

Share on Social Networks: